Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “TMB-H”

13 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 13 of 13 results

Testing effectiveness (Phase 2)UnknownNCT03492918
What this trial is testing

Pembrolizumab in Combination With Paclitaxel in the Hormone Receptor-positive Metastatic Breast Cancer With High Tumor Mutational Burden Selected by Whole Exome Sequencing: Korean Cancer Study Group Trial (KCSG BR20-16)

Who this might be right for
Metastatic Breast Cancer
Yonsei University 30
Testing effectiveness (Phase 2)WithdrawnNCT06331598
What this trial is testing

Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)

Who this might be right for
Solid Tumors
Hoffmann-La Roche
Testing effectiveness (Phase 2)Looking for participantsNCT05086692
What this trial is testing

A Beta-only IL-2 ImmunoTherapY Study

Who this might be right for
Advanced Solid TumorUnresectable Solid TumorClear Cell Renal Cell Carcinoma+34 more
Medicenna Therapeutics, Inc. 115
Testing effectiveness (Phase 2)Study completedNCT03668119
What this trial is testing

Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

Who this might be right for
Pan Tumor
Bristol-Myers Squibb 212
Large-scale testing (Phase 3)Looking for participantsNCT05770102
What this trial is testing

DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

Who this might be right for
MalignancyMalignant NeoplasmLymphoproliferative Disorders+7 more
Cancer Research UK 30
Very early researchWithdrawnNCT03671720
What this trial is testing

Personalized Vaccine Generated by Autologous Dendritic Cells Pulsed With Autologous Whole Tumor Cell Lysate Treat Advanced Solid Tumor Patients With High Tumor Mutation Burden

Who this might be right for
Advanced CancerMetastatic Cancer
Capital Medical University
Testing effectiveness (Phase 2)Looking for participantsNCT06365840
What this trial is testing

IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor

Who this might be right for
TMB-HHistologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors
ImmuneOncia Therapeutics Inc. 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT05199272
What this trial is testing

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

Who this might be right for
Solid TumorClear Cell Renal Cell CarcinomaEpithelial Ovarian Cancer+6 more
23andMe, Inc. 141
Testing effectiveness (Phase 2)Looking for participantsNCT06634875
What this trial is testing

Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)

Who this might be right for
Colorectal Cancer Metastatic
Buzzard Pharmaceuticals 20
Testing effectiveness (Phase 2)UnknownNCT03638297
What this trial is testing

PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer

Who this might be right for
Colorectal Cancer
Sun Yat-sen University 29
Testing effectiveness (Phase 2)Looking for participantsNCT06923761
What this trial is testing

EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)

Who this might be right for
Advanced Solid Malignancy
Grey Wolf Therapeutics 300
Testing effectiveness (Phase 2)UnknownNCT03475953
What this trial is testing

A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors

Who this might be right for
Colorectal Cancer Not MSI-H or MMR-deficientGISTOesophageal or Gastric Carcinoma+12 more
Institut Bergonié 747
Testing effectiveness (Phase 2)Study completedNCT04098068
What this trial is testing

Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D)

Who this might be right for
High Tumor Mutation BurdenHigh TMB (Tumor Mutation Burden)MSS (Microsatellite Stable)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 12